Related Experiment Video

Updated: Jul 5, 2026

Modifying Levels of Maternal Dietary Folic Acid or Choline to Study the Impact of Deficiencies on Offspring Health Outcomes
03:19

Modifying Levels of Maternal Dietary Folic Acid or Choline to Study the Impact of Deficiencies on Offspring Health Outcomes

Published on: June 28, 2024

The safety of mycophenolate mofetil in pregnancy

Cecilia N Pisoni, David P D'Cruz

    Expert Opinion on Drug Safety
    |May 9, 2008
    PubMed

    Insights

    Mycophenolate mofetil (MMF) is used for autoimmune disorders but poses risks during pregnancy. It increases the chance of birth defects and miscarriage, so it should be avoided by pregnant women.

    Area of Science:

    • Immunology
    • Reproductive Medicine
    • Teratology

    Background:

    • Mycophenolate mofetil (MMF) is a crucial immunosuppressant for treating multisystem autoimmune disorders.
    • Autoimmune rheumatological diseases disproportionately affect women of childbearing age, leading to potential MMF exposure during pregnancy.

    Discussion:

    • MMF use in pregnancy is linked to significant risks, including congenital malformations and early pregnancy loss.
    • Specific malformations associated with MMF include external ear defects and orofacial clefts (cleft lip/palate).

    Key Insights:

    • MMF is contraindicated in pregnancy due to teratogenic effects.
    • Healthcare providers must counsel patients of childbearing potential about MMF risks.

    Outlook:

    • Development of safer alternatives for autoimmune conditions in pregnant women is warranted.
    • Emphasis on comprehensive reproductive health counseling for patients on MMF is essential.

    More Related Videos

    Comprehensive Evaluation of the Effectiveness and Safety of Placenta-Targeted Drug Delivery Using Three Complementary Methods09:04

    Comprehensive Evaluation of the Effectiveness and Safety of Placenta-Targeted Drug Delivery Using Three Complementary Methods

    Published on: September 10, 2018

    Related Concept Videos

    Teratogenicity01:07

    Teratogenicity

    The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
    Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics01:23

    Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics

    Respiratory symptoms, such as congestion and cough, commonly accompany respiratory tract conditions. Various medications, such as antitussives, expectorants, and mucolytics, play crucial roles in providing relief.
    Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla.  Benzonatate operates peripherally within the respiratory tract by anesthetizing...
    Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

    Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

    Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
    Cytomegalovirus Disease01:27

    Cytomegalovirus Disease

    Cytomegalovirus (CMV) disease is caused by human cytomegalovirus, a double-stranded DNA virus of the Herpesviridae family. While primary CMV infection is often asymptomatic in immunocompetent individuals, the virus can cause severe disease in neonates and immunocompromised patients. CMV is the most common cause of congenital viral infection in the United States, and a major pathogen in solid organ and hematopoietic stem cell transplant recipients.CMV is transmitted via bodily fluids, sexual...
    Cryptococcal Meningitis01:27

    Cryptococcal Meningitis

    Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
    Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

    Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

    Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...